anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide loquat leaves subjected to a specific treatment for the purpose of being utilized as an item for preventive medicine's enlightenment promotion, and to provide the loquat leaves' usage and their utilization range.  <P>SOLUTION: The loquat leaves subjected to a specific treatment are provided. Besides, a method for storing the loquat leaves and their usage and their utilization range are also provided, respectively. Alternatively, intensity on an O-ring test for the loquat leaves is measured. Reacting and resonating on the meridian and the acupuncture points in the Oriental medicine, the loquat leaves can also be extendingly applied to the preventive medicine, saying "cure disease signs", having the advantage of being utilizable as an item for preventive medicine's enlightenment promotion as well.  <P>COPYRIGHT: (C)2009,JPO&INPIT
BACKGROUND: Guillain-Barré Syndrome (GBS) is caused by immunoglobulin G (IgG) autoantibodies. Efgartigimod, a human IgG antibody Fc fragment that acts as a natural ligand for the FcRn, can increase IgG degradation, which thus may be a promising therapeutic drug for GBS.
CASE PRESENTATION: The two patients presented with postinfectious and acute flaccid paralysis. On admission, they were bedridden. Nerve conduction studies indicated peripheral neuropathy. GBS was suspected and they are treated with two doses of efgartigimod (10 mg/kg) within 5 days. Their muscle strength improved gradually and 4 weeks after the initial dose, they could walk independently. Following the first dose, Patient 1 complaint of muscle soreness, which subsided the next morning. Patient 2 was intubated due to respiratory failure the day after the initial dose, and did not report other adverse effects.
DISCUSSION: In GBS patients, two doses of efgartigimod (10 mg/kg) were effective in rapidly improving muscle strength, with a satisfactory safety profile. The findings suggest a potential role for efgartigimod in modifying the disease process in GBS patients.
CONCLUSION: Efgartigimod seems effective and safe in the treatment of GBS. This study indicates the potential role of efgartigimod as a novel treatment option for GBS. Well-designed clinical trials should be conducted.
Background: Biliary fistula (BF) is one of the most common sources of post hepatectomy morbidity. International Study Group of Liver Surgery (ISGLS) define BF as increased bilirubin concentration in the drain at least 3 times greater than the serum bilirubin concentration on or after postoperative day (POD) 3. BF is graded into grade A, B and C, based on the clinical impact on the postoperative course. Considering ISGLS definition, the incidence of BF ranges from 4,4% to 27,2%. The definition developed in Humanitas Research Hospital (HRH), defines BF as bilirubin concentration in the drain fluid greater than 10 mg/dL on or after POD 3. In this case, the incidence is around 8%. Various topical haemostatic agents have been developed for liver resection area management their usefulness in preventing BF by using a sealing product on the resection surface still remains unclear and needs to be assessed.

Objective: this study aimed to assess the clinical validation of Hemopatch to prevent post-operative biliary fistula. Secondarily, it is aimed to evaluate the clinical validity of the two proposed definition of biliary fistula.

Methods: According to the incidence of BF in our previous series (considering ISGLS definition), we designed a randomized controlled study on 220 patients, who underwent hepatic resection from 2018 to 2020. Patients were randomized to treatment group A (Hemopatch) and standard group B (Tisseal and Tabotamp). Both ISGLS and HRH definitions of BF were considered. All patients were systematically drained. Drains were maintained at least 5 days, and bilirubin was measured on PODs 3, 5, and 7. Drains were removed if the bilirubin concentration in the drain fluid was less than 10 mg/dL on POD 7. A statistical analysis to compare perioperative variables between two groups was performed. Then, a multivariate analysis was performed to identify potential risk factors for BF.
The invention relates to a compounded traditional Chinese medicine, in particular to a medicine for curing diabetes. The medicine solves the problems that the existing foreign medicine has more side effects in curing diabetes, while traditional Chinese medicine has long course of treatment, slow efficacy, and unreasonable compatibility of medicines. The medicine is made up of the following raw materials by weight: 25 portions to 35 portions of selaginella pulvinata, 10 portions to 20 portions of boea hygrometrica, 8 portions to 12 portions of brass fiber; and 28 portions to 32 portions of pyrrosia lingua. The medicines mentioned earlier are selected by priority and scientific compatibility proportion; in this way, the medicines act in concert with each other and complement each other; synergetic effect of the medicines can enhance the efficacy, addressing both the symptoms and root causes. The compounded traditional Chinese medicine has the functions of quenching thirsty and soothing troubles, tonifying kidneys, deintoxication, nourishing the blood and adjusting blood sugar in human body, clearing heat and promoting fluid, nourishing spleen and enriching Qi, and adjusting blood-fat. Clinical tests prove that the medicine can lower the level of blood sugar for diabetics who have meals within 2 hours, maintain the low level of blood sugar for a longer time, and lower the level of glycerol and cholesterin for patients with hyperlipidemia.
Although many schizophrenia patients currently take oral antipsychotic medications, it is estimated that up to 75% of them have difficulty adhering to the daily oral regiment. Long-acting injectable formulations may eliminate the need for daily medication and enhance patient compliance with the treatment regimen. Traditionally, patients experiencing an episode of schizophrenia are first treated with oral medications until they are stabilized, and then injectable long-acting formulations are given. This is an open, multicenter, randomized Phase IV trial in patients after an acute episode of schizophrenia. Patients will be in the trial for 6 months. One treatment group will receive injections starting at baseline (early initiation); the other group will start with treatment as usual at baseline and begin injections at Week 12 (late initiation). Assessment of effectiveness include Positive And Negative Syndrome Scale (PANSS), in order to measure symptoms of schizophrenia; Clinical Global Impression - Severity (CGI-S), measuring overall severity of illness; Global Assessment of Functioning (GAF), assessesing overall psychological, social, and occupational functioning; and Quality of Life Questionnaire SF-12, measuring overall health status. Safety evaluations include the Extrapyramidal Symptoms Rating Scale (ESRS), incidence of adverse events throughout the study, and vital signs (pulse, blood pressure). The study hypothesis is that early initiation of long-acting risperidone injections is not inferior to late initiation as measured by changes in PANSS total score from baseline through endpoint (after 6 months). Risperidone, long-acting formulation for intramuscular injections (25 to 50 mg (maximum)), given every 14 days through 6 months, starting at baseline or Month 3. Treatment as usual for 3 months for late initiation group
The present invention relates to a herba agastachis summer-heat eliminating soft capsule and a preparation method thereof, which belongs to the technical field of traditional Chinese medicines. The present invention is used for reasonably preparing fillings and a soft capsule shell to prepare a soft capsule successfully and preventing the problems of crack and oil leakage. The soft capsule is composed of the fillings and the soft capsule shell, wherein the fillings comprise herba agastachis summer-heat eliminating extract dry powders and a filling agent, and the fillings are characterized in that the weight ratio of the herba agastachis summer-heat eliminating extract dry powders and the filling agent is from 1: 1.9 to 2.3. The product of the present invention optimizes the appropriate mixture ratio of the filling agent and the medicine extract dry powders by repeated test comparison in each technological process of medicament preparation, so that a medicine liquor is in a good suspension condition, and medicine powders are distributed uniformly and place without sinking and gathering. The present invention solves the problem that the fillings have poor flowability to result in blocking pipes and difficult pelleting in the process of capsule preparation. The present invention has the advantages of high and uniform medicine extract content and reliable medicine effect, the mixture ratio of the soft capsule shell is selected, and the capsule has ideal results in the aspects of capsule shape, color, disintegration, etc. after pelleting capsule wall materials.
PURPOSE:To obtain the titled emulsion external preparation having excellent stability, by blending a fatty acid which is liquid at ordinary temperature with a carboxylic acid dialkyl ester. CONSTITUTION:The aimed emulsion external preparation containing (A) 0.5-5.0wt.% diclofenac sodium which is a nonsteroid antiinflammatory and analgesic agent, (B) 0.5-20wt.% fatty acid which is a liquid at ordinary temperature, preferably 6-18C fatty acid (especially oleic acid, linoleic acid, etc.) and (C) 0.25-50wt.% carboxylic acid dialkyl ester, e.g. 12-22C adipic acid dialkyl ester or 14-22C sebacic acid dialkyl ester as essential ingredients. A blend ratio of B to C is preferably 1:1-1:5. Each ingredient is preferably blended at the following amount: A=1.0-3.2%; B=1.0-10%; C=0.5-20% and when an oil content having lower polarity than fatty acid and nonionic surfactant are further blended, emulsifying stability of the agent is improved.
Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline. These selective serotonin reuptake inhibitors (SSRIs) have limited efficacy. Furthermore, there is a lack of efficacious pharmacotherapy for treatment-resistant PTSD; PTSD remains a chronic and sometimes debilitating condition. New research into other treatment options for PTSD are warranted.

Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Psilocybin has received breakthrough designation for treatment of depression. Research on psilocybin has shown that it facilitates fear extinction in mice and promotes neuroplasticity, increasing neurogenesis, spinogenesis and synaptogenesis. These properties may contribute to antidepressive and anxiolytic effects. Psilocybin also reduces activity in the amygdala during threat responses; decreased amygdala reactivity is correlated with positive mood. This is particularly relevant since individuals with PTSD showed increased reactivity in the amygdala, which may increase the ability to process traumatic memories. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.
Acute coronary syndrome is a high mortality and costly disease. Antiplatelet therapies, including aspirin and P2Y12 antagonist, play important roles at the acute and subacute stage treatment for acute coronary syndrome, especially after coronary stent implantation. Patients with decreased estimated glomerular filtration rate (eGFR) experience higher cardiovascular morbidity and mortality. Clopidogrel, one of P2Y12 receptor antagonists, inhibits the receptor's activation by blocking its interaction with ADP. However, the efficacy of clopidogrel shows substantial variation and residual platelet reactivity, which is related to adverse cardiovascular outcome, especially in impaired renal function. Our study aims to check the platelet inhibition rate comparing both medication with a cross-over study among CKD subjects and ACS condition.
Diazepam Injection is classified by the Drug Enforcement Administration as a schedule IV controlled substance.

Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of diazepam. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving diazepam or other psychotropic agents because of the predisposition of such patients to habituation and dependence.
Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly. Patients undergo bone marrow biopsy at screening and during follow-up. Patients undergo blood specimen collection on study.
OBJECTIVES: I. Determine the maximum tolerated dose and dose limiting toxicity of yttrium Y 90 humanized anti-CD22 LL2 (Y90 MOAB hLL2) in combination with salvage chemotherapy and autologous peripheral blood stem cell rescue in patients with recurrent or refractory B-cell malignancies. II. Study the effect of chemotherapy on the uptake of Y90 MOAB hLL2 into tumor sites and normal organs by pretherapy imaging using indium In 111 humanized LL2 and intratherapy imaging. III. Determine the extent and duration of tumor response in patients receiving this regimen.

OUTLINE: This is a dose escalation study of yttrium Y 90 humanized anti-CD22 monoclonal antibody LL2 (Y90 MOAB hLL2). Patients receive filgrastim (G-CSF) subcutaneously daily for 5 days and undergo harvest of peripheral blood stem cells (PBSC) on 2 or more consecutive days. If an adequate number of CD34+ cells are not harvested, autologous bone marrow may be used. Chemotherapy-induced mobilization with filgrastim allowed. Patients undergo pretherapy imaging with indium In 111 humanized LL2 (In111 hLL2) for up to 40 minutes on day -7. Patients receive Y90 MOAB hLL2 for up to 40 minutes on day 0 plus In111 hLL2, followed by Y90 MOAB hLL2 alone on day 3. Patients receive ifosfamide IV over 1 hour, cisplatin IV over 2 hours, and cytarabine IV over 2 hours on days 1 and 4. Oral etoposide is given daily on days 1-7. PBSC or bone marrow is reinfused on days 9-14, depending on MOAB clearance. Cohorts of 3-6 patients receive escalating doses of Y90 MOAB hLL2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity. Patients are followed weekly for 2 months, monthly for 6 months, and then every 6 months for 5 years.

PROJECTED ACCRUAL: Approximately 15-24 patients will be accrued for this study within 2-2.5 years.
RATIONALE: Restoration of blood flow after out-of-hospital cardiac arrest (OHCA) is associated with inflammation that causes cellular injury. The extent of this reperfusion injury (RI) is associated with the duration of ischemia and adequacy of resuscitation. Remote ischemic conditioning (RIC) consists of repeated application of non-lethal ischemia then reperfusion to a limb distal to the heart by inflating a blood pressure (BP) cuff. Trials in animal models in cardiac arrest and in humans with acute infarction show RIC reduces RI.
OBJECTIVE: We sought to demonstrate the feasibility and safety of RIC in patients resuscitated from OHCA and transported to hospital.
METHODS: This study was conducted under exception from informed consent (EFIC) for emergency research. Eligible subjects were randomized with masked allocation to control (standard care) versus intervention (standard care and RIC). Included were adults with non-traumatic OHCA. The primary outcome was attrition, the proportion of patients enrolled and not on allocated therapy for the study duration. Key secondary outcomes were survival to discharge, neurologic status at discharge, hospital-free survival, and adverse events. Results were summarized descriptively as recommended for pilot studies.
RESULTS: N = 30 patients were enrolled (n = 14 control, n = 16 intervention). Mean age of enrolled patients was 52.5 ± 16.2 years. Eight (27%) were female gender and 7 (23%) had a shockable first recorded rhythm. 100% of enrolled patients completed their allocated study intervention (i.e., 0% attrition). The RIC group had 7 (44%) survival to discharge and median Rankin score of 6 (IQR 1, 6) at discharge as compared to the standard care group which had 6 (43%) survival to discharge and median Rankin score of 6 (IQR 1.5, 6) at discharge. A single patient (6%) in the intervention group had transient occlusion of their upper extremity intravenous line, which immediately resolved on repositioning of the blood pressure cuff.
CONCLUSION: Application of RIC to patients resuscitated from CA and transported to an ED is feasible and safe. An adequately powered trial is required to assess whether RIC is effective at decreasing morbidity and mortality after CA.
Using a conservative estimate of 7 adolescents per cycle and 3 testing cycles, 21 adolescents will take part in usability testing of the PainSquad+ prototype. Recruitment will be conducted in a single hematology/oncology division of a metropolitan and university-affiliated pediatric tertiary care center in Toronto, Canada. This site hosts one of the largest cancer programs in North America, with approximately 350 new diagnoses each year. Based on our previous research at this site, 72 ± 4% (M ± SD; range = 67-75%) of eligible AWC agreed to participate in similar studies (unpublished data). Convenience sampling will be used to recruit eligible individuals. The testing procedures will commence after eligibility is assessed, informed consent is obtained, and demographic and baseline outcome data are collected. Inclusion criteria will be: (a) aged 12-18 years, (b) able to speak and read English, (c) actively undergoing cancer treatment on an in- or out-patient basis, (d) being at least 3 months from diagnosis and (d) having self-reported pain of any intensity in the week immediately prior to recruitment. Exclusion criteria will be: (a) one or more major co-morbid (medical or psychiatric) conditions that would preclude use of a smartphone, and (b) palliative/end-of-life patients.
This happens on Day 0. Screening for EGD, biopsy samples from esophagus, stomach, gastrointestinal junction, and duodenum AE's.
Methods for isolating patched genes, including the mouse and human patched genes, as well as invertebrate patched genes and sequences, are provided. Decreased expression of patched is associated with the occurrence of human cancers, particularly basal cell carcinomas of the skin. The patched and hedgehog genes are useful in creating transgenic animal models for these human cancers. The patched nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like. The DNA is further used as a diagnostic for a genetic predisposition to cancer, and to identify specific cancers having mutations in this gene.
PROBLEM TO BE SOLVED: To provide a method and a device for coating which suppresses occurrence of a fault by a foreign matter by preventing a coating liquid from remaining on the wall surface of a hose. SOLUTION: The coating liquid 11 in a tank 31 is supplied to a die 10 through a flexible hose 26. The hose 26 consists of a Teflon(R) hose and a double-structured cover hose for covering this Teflon(R) hose. The Teflon(R) hose is constituted in the shape of a pipe which has 8 to 10 mm inner diameter, 1 to 1.5 mm wall thickness and a smooth inner peripheral surface. The inner cover hose consists of a blade hose made of vinyl chloride having 15 mm inner diameter and 1.5 mm wall thickness. The outer cover hose consists of a blade hose made of vinyl chloride having 25 mm inner diameter and 2 mm wall thickness. Occurrence of the fault by the foreign matter is suppressed by eliminating the infiltration and remaining of the coating liquid to the wall surface of the Teflon(R) hose due to to use of this Teflon(R) hose 35.  An external force applied to the Teflon(R) hose 26 is dispersed by this triple structure and the hose 26 becomes difficult to break.
PROBLEM TO BE SOLVED: To obtain a composition that has markedly high hardness, manifests markedly swift disintegration rate and can form tablets or the like having good properties by using directly compressable starch flour. SOLUTION: This composition comprises (A) non-birefringent starch granules that are partially swollen and have a certain level of smoothness, (B) non- swollen and bire-fringent granules and (C) at least one of other excipients in which the ratios of the component B to the component A is 1/5-5/1. The ratio of the directly compressable starch to the excipient is preferably 1/10-10/1. In a preferred embodiment, this composition additionally 0.01-80 wt.% of active ingredients, for example, pharmacologically active substances, perfumes, sweeteners, detergents or the like. The starch to be used here has an average particle size of >=50 μm and a moist content of 3-15%. This composition can be used for giving tablets and other unit drug forms of good qualities.
The process comprises reaction of dimethylamine with cyanuryl chloride in a solvent made as a mixt. of aq. NaOH soln. and an organic solvent. The organic solvent is e.g. benzene, toluene or xylene, and the reaction takes place in the presence of a phase transfer catalyst such as triethylbenzyl ammonium chloride. - The prod., which has formula (I) is used e.g. as a pesticide and in lung and ovarian cancer treatment.